Poseida Therapeutics Inc reports results for the quarter ended in March - Earnings Summary

Poseida Therapeutics

10/05/2023 13:01

* Poseida Therapeutics Inc  PSTX.OQ  reported a quarterly
adjusted
loss of 45 cents​​ per share for the quarter ended in March. The
mean expectation of four analysts for the quarter was for a loss
of 45 cents per share.
    * Revenue rose 620.8% to $10.34 million from a year ago;
analysts
expected $9.38 million. 
    * Poseida Therapeutics Inc's reported EPS for the quarter
was a
loss of 45 cents​.
    * The mean earnings estimate of analysts had risen by
about 26.8%
in the last three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company. 
    * Poseida Therapeutics Inc shares had risen by 10.4% this
quarter and lost 35.8% so far this year.
    * The company reported a quarterly loss of $38.85 million.
    * Wall Street's median 12-month price target for Poseida
Therapeutics Inc is $14.00 
    * The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 6 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell." 

This summary was machine generated from LSEG Refinitiv data May
10 at 12:01 p.m. UTC. ​All figures in US dollars unless
otherwise stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Mar. 31 2023      -0.45          -0.45          Met
 Dec. 31 2022      -0.22          -0.39          Missed
 Sep. 30 2022      -0.65          0.92           Beat
 Jun. 30 2022      -0.76          -0.69          Beat